You are in:Home/Publications/Serum Interleukin-36 in Pityriasis Rosea: A Potential Biomarker for Disease Severity

Dr. Ghada Mohamed Abdel Khalek Abdel Razik :: Publications:

Title:
Serum Interleukin-36 in Pityriasis Rosea: A Potential Biomarker for Disease Severity
Authors: EMAN M. SANAD, MD; MAYS IBRAHIM, MBBCH; MAHA RACHWAN, MD; and GHADA M. SHAMS, MD
Year: 2023
Keywords: Not Available
Journal: The Journal of clinical and aesthetic dermatology
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link:
Full paper Ghada Mohamed Abdel Khalek Abdel Razik_paper7.pdf
Supplementary materials Not Available
Abstract:

OBJECTIVE: Pityriasis rosea (PR) is a self-limiting acute rash with unclear etiology and pathogenesis. The cytokine pro le of PR is an infrequently investigated  eld of research. The aim of this study was to assess the level of IL-36 in sera of patients with PR and its possible interrelation with disease severity. METHODS: Forty patients with PR were included in this case-control study, and 40 comparable healthy control subjects. Severity was assessed using pityriasis rosea severity score (PRSS) and serum IL-36 was assessed using ELISA. RESULTS: Serum IL-36 was signi cantly higher in patients (30.36±12.35) pg/mL compared to control subjects (18.76±10.24) pg/mL (P=0.003). It correlates positively with severity as assessed by PRSS (r= 627, P= 0.003). Patients who reported a history of COVID-19 had signi cantly higher levels of IL-36 (32.66±11.79) pg/mL compared to those who have not (17.33±2.08) pg/mL (P= 0.000).

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus